Lucy Flanders (@lucykflanders) header
Lucy Flanders (@lucykflanders) profile picture

Consultant GI Medical Oncologist (HPB, HCC and CUP) Royal Free Hospital

London, England
Joined June 2015
Photo by Lucy Flanders (@lucykflanders)Photo by Lucy Flanders (@lucykflanders)Photo by Lucy Flanders (@lucykflanders)Photo by Lucy Flanders (@lucykflanders)Photo by Lucy Flanders (@lucykflanders)Photo by Lucy Flanders (@lucykflanders)Photo by Lucy Flanders (@lucykflanders)Photo by Lucy Flanders (@lucykflanders)Photo by Lucy Flanders (@lucykflanders)Photo by Lucy Flanders (@lucykflanders)
Lucy Flanders retweeted
Trastuzumab plus nivolumab with GemCis as 1L therapy for HER2-positive unresectable BTC: pls 1b/2 trial @NatureMedicine doi.org/10.1038/s41591-026-0… 👉ORR 55%, DCR 95% 👉mPFS 10.6 mo, mOS nr 🧐Promising, HERIZON BTC & DESTINY-BTC awaited
2
20
1
42
2,580
Lucy Flanders retweeted
🔥off the press🔥 Pre-Liver Transplant Immunotherapy and Post-Transplant Outcomes in HCC: Global LIFT-HCC-1 Study doi.org/10.1016/j.cgh.2026.0… 👉408 pts 👉Tumor burden & AFP at LT associated with HCC recurrence 👉Rejection associated with non-HBV, irAEs, age, shorter ICI washout 🧐pre-LT ICI feasible, clinical utility needs to be established @myESMO @EASLnews @ILCAnews
1
33
2
65
4,925
Looking forward to a day of education! @myESMO @DrAngelaLamarca
2
44
Lucy Flanders retweeted
There were A LOT of updates in KRAS trials during the month of October for colorectal cancer. - new locations , new arms, new trials. KRAS trials are moving full steam ahead! Here's a link to updates in October. clinicaltrials.gov/search?co…
4
15
1,441
Lucy Flanders retweeted
Key Updates in GI Oncology From ESMO 2026 #ESMO26 presented important Phase III findings across gastrointestinal oncology, including significant survival benefits and new evidence supporting treatment optimization. Key highlights: ▫️ G-HOPE-001 & CLARITY-Gastric01: CLDN18.2-directed ADCs demonstrated significant OS benefits in previously treated gastroesophageal cancer, although CLARITY-Gastric01 did not meet its co-primary PFS endpoint. ▫️ HERIZON-GEA-01 & KC-WISE: Updated survival findings strengthened the evidence for HER2-directed therapies in gastric and gastroesophageal cancer. ▫️ HARMONi-GI1: Ivonescimab plus chemotherapy significantly improved OS compared with durvalumab-based treatment in advanced biliary tract cancer. ▫️ PRABITAS & LOMAC: Both Phase III trials met their prespecified noninferiority endpoints, with reductions in treatment-related toxicity or adverse events. Takeaway: ESMO 2026 provided significant survival findings for biomarker-directed therapies, alongside evidence supporting treatment optimization. PRABITAS and LOMAC met their respective OS and DFS noninferiority endpoints, with reductions in selected adverse events. @oncodaily @OncoDailyGI @myESMO oncodaily.com/gastrointestin… #ESMO26 #ESMO2026 #OncoDaily #GIOncology
1
8
690
ESMO2026: INCB161734 in KRAS G12D-mut mPDAC Promising early data investigational KRAS G12D inhibitor+chemo 📊ORR 69% with GEM/abraxane vs 89% with mFOLFIRINOX 📈6-month PFS 80% vs 90% 🔬ctDNA responses 74% vs 69% Responses appear durable in some pts but follow-up remains short
1
1
2
235
⚠️ Toxicity remains key: GI adverse events and chemotherapy dose modifications were common, particularly with mFOLFIRINOX Encouraging activity in KRAS G12D-mutant PDAC, but these small, early-phase cohorts require longer followup & confirmatory studies #ESMO #GIOncology #PDAC
1
79
ESMO 2026 | MASTERPLAN Can SBRT improve outcomes in high-risk localised&locally advanced PDAC? 🔹12m locoregional recurrence 20.2% vs 52% (p=0.022) 🔹PFS 11.9 vs 6.3m (HR 0.44) 🔹OS 22 vs 14m (HR 0.45) Promising results-but patient selection& ph3 confirmation matter #ESMO26
1
2
175
🚨 ESMO 2026 | HARMONi-GI1 Phase III, 1L advanced biliary tract cancer: ivonescimab (PD-1 × VEGF) + GemCis vs durvalumab + GemCis (n=682) 📊 OS: 14.9 vs 12.1 m (HR 0.75; p=0.0031) 📊 PFS: 8.4 vs 5.8 m (HR 0.61) 📊 ORR: 53.8% vs 32.5% The bispecific era is gathering pace. 🧬
1
1
2
189
🔎 HARMONi-GI1 | Safety Gr3–4 AEs: 82.0% ivonescimab+GemCis vs 72.3% durva+GemCis Serious AEs similar (43.4% vs 43.7%); gr ≥3 IO-related AEs 4.1% in both Could dual PD-1/VEGF reshape 1L BTC treatment? Longer followup &validation beyond this trial population needed #ESMO26
122
🧬 #ESMO26 EMERALD-3:can STRIDE-based therapy preserve liver function in intermediate-stage HCC? 📊 Exploratory analyses suggest: 👉 Liver function (ALBI & Child-Pugh scores) remained broadly stable during treatment. 👉 No clear signal of deterioration with combination therapy
1
1
137
🔎 An important question: do pooled mean scores mask clinically meaningful within-patient changes in liver function? Preserving hepatic reserve is crucial in HCC — but these exploratory findings need cautious interpretation #HCC #LiverCancer #Immunotherapy #TACE
56
🧬 #ESMO26: BGB-B2033, a GPC3 × 4-1BB bispecific antibody, shows promising activity in advanced HCC. 📊 Phase I (n=94): • ORR 30% at 1,000 mg; 36% at 450 mg in dose optimisation • 450 mg Q3W selected as RP2D • Manageable safety profile; grade ≥3 TRAEs in 5% • IRR 8.5%
1
2
189
🔬 By conditionally activating 4-1BB on GPC3-expressing tumour cells, BGB-B2033 aims to stimulate targeted T-cell activity while limiting off-tumour toxicity. Promising early data. Combination studies with ICIs will be important to watch. #HCC #LiverCancer #Immunotherapy
1
97
🧵 ESMO 2026: ACTICCA-1 Can adj GemCis improve outcomes after curative-intent resection of BTC? 📊 Key results 🔹 2-year DFS: 52% vs 44% (HR 0.82; p=0.058) 🔹DFS: 23.3 vs 20.6 🔹OS: 58.1 vs 48.2 (HR 0.82; p=0.103) ❗Neither DFS nor OS reached statistical significance
1
1
173
⚠️ GemCis ⬆️ toxicity,predom haematological Take🏠 ACTICCA-1 addresses unmet need for better adj therapy in BTC, but does not establish GemCis as superior to cape 🔦Search for more effective adj strategies continues, including peri-op IO approaches #ESMO26 #BiliaryTractCancer
91
Lucy Flanders retweeted
Replying to @YJanjigianMD
@YJanjigianMD and #JamesLarkin on the main topics and data that will be presented at @myESMO #ESMO26 Annual Conference 🦠Cancer Vaccine - very hot topic! 💉ADCs in many settings 👀Follow the “What oncologist should know about” special sessions 🆕 #ESMOAmbassadors
7
17
1,016
Lucy Flanders retweeted
🚀Upper GI oral abstracts #ESMO26 Day 1 summary results 1) Arcotatug tavatecan improved PFS in CLDN18.2+ G/GEJA in the 3L+ setting 2) SANO trial, OS at 5 years similar between active surveillance and surgery in patients with oesophageal cancer and a complete clinical response after nCR, despite more distant metastasis 3) Adding pembrolizumab to dCRT did not improve EFS in untreated unresectable esophageal or GEJ cancer with PD-L1 CPS ≥10 4) Daraxonrasib demonstrated consistent OS benefit in different RAS mutatin subgroups in RASolute-302 5) mKRAS-specific lymph node targeted amphiphile immunotherapy in PDAC did not met primary DFS endpoint. 6) Zani + CT +/- tisle keep OS benefit in at IA2 of HERIZON-GEA-01 7) Anbenitamab plus ChT improved OS in patients with HER2-positive GC/GEJC adenoca after previous trastuzumab 8) TQB2102 (HER2 bispecific antibody-drug conjugate) plus bemotrizumab and capecitabine demonstrates promising antitumor activity in 1L of advanced GC/GEJC 9) Dostarlimab in Pts with localized dMMR/MSI-H GEA led to a 62.5% 1y-cCR at the first interim analysis, enabling organ preservation. 10) FOLFIRI and Ram vs paclitaxel in taxan-pretreated GEA imporved PFS but no OS 11) Stage II–IIIB gastric cancer after D2 resection, four months of adjuvant XELOX was noninferior to six months for 3-year DFS 12) Adding durvalumab to dCRT in locally advanced esophagus carcinoma did not improve PFS 13) Adding SBRT to MFOLFIRINOX in high risk, borderline resectable or locally advanced pancreatic cancer mproved LRR and PFS 14) FGFR2b expressing GC/GEJ with co-existing FGFR2 amp may define a biologically distinct subset with potential sensitivity to bemarituzumab #cancer #oncology #MedX #GI #gastrointestinal @OncoAlert
1
34
55
3,720